MarketPulse

complement inhibitor

2 articles
BenzingaBenzinga··Benzinga

Biogen Closes $41-Per-Share Acquisition of Apellis, Adding $689M Revenue Pipeline

Biogen closes Apellis acquisition at $41/share, gaining two commercial products with $689M in 2025 revenue. Deal expected accretive to EPS by 2027.
APLSBIIBacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Fabhalta Shows 49% Slowing of Kidney Decline in Landmark IgAN Study

Novartis' Fabhalta slowed kidney function decline by 49.3% in Phase III trial, with FDA priority review granted for IgA nephropathy treatment.
NVSFDA approvalkidney disease